Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018–2020)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018–2020)
Authors
Keywords
-
Journal
INFECTION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-19
DOI
10.1007/s15010-021-01668-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK
- (2020) Jean L Mbisa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
- (2020) Dominique L. Braun et al. Viruses-Basel
- Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
- (2020) Mark J. Siedner et al. Nature Communications
- Mutations altering acetylated residues in the CTD of HIV-1 integrase cause defects in proviral transcription at early times after integration of viral DNA
- (2020) Shelby Winans et al. PLoS Pathogens
- Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018
- (2020) Yun Lan et al. Infection and Drug Resistance
- Lack of HIV-1 integrase inhibitor resistances among 392 antiretroviral-naïve subjects in a tertiary care hospital in Beijing, China
- (2019) Lifeng Liu et al. AIDS
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance
- (2019) Philip L Tzou et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013
- (2016) A. Zoufaly et al. INFECTION
- Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
- (2016) Sui-Yuan Chang et al. Scientific Reports
- Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.
- (2015) M. Casadellà et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Antiretroviral therapy: dolutegravir sets SAIL(ING)
- (2013) Mark A Boyd et al. LANCET
- Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011
- (2013) Fatemeh Jahanbakhsh et al. PLoS One
- Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
- (2012) Mark A. Winters et al. PLoS One
- In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
- (2011) Nicolas A. Margot et al. ANTIVIRAL RESEARCH
- HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
- (2011) Jose-Luis Blanco et al. JOURNAL OF INFECTIOUS DISEASES
- Elvitegravir: a once daily alternative to raltegravir
- (2011) Belete Ayele Desimmie et al. LANCET INFECTIOUS DISEASES
- MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods
- (2011) K. Tamura et al. MOLECULAR BIOLOGY AND EVOLUTION
- The evolution of HIV: Inferences using phylogenetics
- (2011) Eduardo Castro-Nallar et al. MOLECULAR PHYLOGENETICS AND EVOLUTION
- Appreciating HIV Type 1 Diversity: Subtype Differences in Env
- (2009) Rebecca M. Lynch et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors
- (2009) A. Low et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Raltegravir: a new choice in HIV and new chances for research
- (2009) Sean Emery et al. LANCET
- Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
- (2008) Vincenzo Summa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors
- (2008) Soo-Yon Rhee et al. Retrovirology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started